Palliative CarePEACENCT07338071
Antithrombotic Therapy at the End of Life: The PEACE Study
An observational study of Palliative Care, run by Fondazione Policlinico Universitario Agostino Gemelli IRCCS at 1 site in Italy.
Trial summary
"Antithrombotic Therapy at the End of Life: The PEACE Study" is a multicenter, non-profit, cross-sectional observational study. In the absence of shared guidelines, therapeutic decisions on antithrombotic drugs vary significantly according to healthcare professional training and national context, resulting in marked… Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Palliative Care
- What is being tested?
- antithrombotic drugs
- How many people
- 410 participants
- Where
- 1 siteItaly
- Study dates
- Jan 2026to Nov 2027
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: The study sample will consist of hospitalized patients referred to a Palliative Care pathway
Who may be able to join
- Adults (≥18 years) hospitalized and referred to Palliative Care (home-based or residential) at the discretion of the attending physician.
- Signed informed consent
Who cannot join
- none
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Italy1 site
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Roma, RM, 00168
About this study
"Antithrombotic Therapy at the End of Life: The PEACE Study" is a multicenter, non-profit, cross-sectional observational study. In the absence of shared guidelines, therapeutic decisions on antithrombotic drugs vary significantly according to healthcare professional training and national context, resulting in marked variability in prescribing practices. This study aims to describe the prevalence of antithrombotic prescriptions in patients referred to Palliative Care.
- Conditions
- Palliative Care
- Being tested
- antithrombotic drugs
- Keywords
- antithrombotic therapy, end of life, palliative care
- Medical subject headings
- Death
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
antithrombotic drugsDrug
use of antithrombotic drug
What is being measured
The primary outcome is the main question the study is designed to answer.
Prevalence of antithrombotic drug use
Calculation of the prevalence of antithrombotic drug use in hospitalized patients referred to Palliative Care pathway.
Measured: at enrollment
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted13 Jan 2026
- Study startJan 2026 (estimated)
- Primary completionNov 2027 (estimated)
- Study completionNov 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Palliative CareStudies of the same condition, open and under way.
- More trials run by Fondazione Policlinico Universitario Agostino Gemelli IRCCSThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Cross-sectional
- Enrolment
- 410 participants (estimated)
Sponsor and investigators
- Sponsor type
- University, hospital or other
- Collaborators
- Ospedale Cristo Re - Roma, San Giovanni Addolorata Hospital
- Responsible party
- Principal investigator, Pola Roberto, Fondazione Policlinico Universitario Agostino Gemelli IRCCS
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07338071
- Sponsor's protocol ID
- ID 3722
- Acronym
- PEACE
- Status last verified
- Dec 2025
- First submitted
- 3 Jan 2026
- Last updated
- 13 Jan 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 13 Jan 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Antithrombotic Therapy at the End of Life: The PEACE Study
- ClinicalTrials.gov ID
- NCT07338071
- Acronym / sponsor ID
- PEACE / ID 3722
- Conditions
- Palliative Care
- Keywords
- antithrombotic therapy, end of life, palliative care
- Study type
- Observational
- Recruitment status
- Not yet recruiting
- Enrolment
- 410 participants (estimated)
- Lead sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCSUniversity, hospital or other
- Collaborators
- Ospedale Cristo Re - Roma, San Giovanni Addolorata Hospital
- Study start
- Jan 2026 (estimated)
- Primary completion
- Nov 2027 (estimated)
- Study completion
- Nov 2027 (estimated)
- First posted
- 13 Jan 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
"Antithrombotic Therapy at the End of Life: The PEACE Study" is a multicenter, non-profit, cross-sectional observational study. In the absence of shared guidelines, therapeutic decisions on antithrombotic drugs vary significantly according to healthcare professional training and national context, resulting in marked variability in prescribing practices. This study aims to describe the prevalence of antithrombotic prescriptions in patients referred to Palliative Care.
Study design
- Observational model
- Cohort
- Time perspective
- Cross-sectional
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- The study sample will consist of hospitalized patients referred to a Palliative Care pathway
Key inclusion criteria (2 listed)
- Adults (≥18 years) hospitalized and referred to Palliative Care (home-based or residential) at the discretion of the attending physician.
- Signed informed consent
Key exclusion criteria (1 listed)
- none
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| antithrombotic drugsuse of antithrombotic drug | Drug | – |
Primary outcome
Prevalence of antithrombotic drug use
Time frame: at enrollment
Calculation of the prevalence of antithrombotic drug use in hospitalized patients referred to Palliative Care pathway.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 13 Jan 2026.
- Individual participant dataSharing planned: No
Related trials for Palliative Care
Not yet recruitingObservational study
IN-TALK: Co-producing a Hospice Intimacy Support Toolkit in England
Communication About Intimacy Needs in Hospice and Palliative Care
Not yet recruitingPhase 2
Psilocybin With Psychotherapy for Improving Chronic Pain in Cancer Patients Requiring Opioids
Hematopoietic and Lymphatic System Neoplasm, Malignant Solid Neoplasm
RecruitingPhase 1/2
Interstitial Photodynamic Therapy Following Palliative Radiotherapy in Treating Patients With Inoperable Malignant Central Airway Obstruction
Malignant Solid Neoplasm
Active, not recruiting
LiverPAL: A Trial of Inpatient Palliative Care for Patients With Advanced Liver Disease
Liver Disease Chronic, End Stage Liver DIsease
Not yet recruiting
Comparing Radiotherapy Dose Strategies for Symptom Relief in Large Solid Tumors
Solid Tumor
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Palliative Care, run by Fondazione Policlinico Universitario Agostino Gemelli IRCCS at 1 site in Italy.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 13 Jan 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Italy. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Roberto Pola (+390630157075, roberto.pola@policlinicogemelli.it), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Prevalence of antithrombotic drug use (time frame: at enrollment). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 13 Jan 2026.